1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Key Pharma News 06 OCTOBER 2014

Key Pharma News 06 OCTOBER 2014

  • October 2014
  • -
  • Espicom Business Intelligence
  • -
  • 45 pages

Industry Trend Analysis - Bayer's De-Diversification Presents Opportunities For Oncology Segment
Industry Trend Analysis - Licence Agreement Helps Gilead Face Down Pressure
Industry Trend Analysis - AstraZeneca/Lilly Deal Shares Risk Over Potential Blockbuster Alzheimer's Drug
Industry Trend Analysis - Novartis Backs Away From The Fierce Nature Of HCV Market
Industry Trend Analysis - Companion Diagnostics Could See New Alzheimer's Drugs Succeed
Industry Trend Analysis - Combinations Key To Pfizer's Immuno-Oncology Success
Industry Brief - Merck Serono Enters Partnership With Lupin
Industry Trend Analysis - BI Enhances Oncology Pipeline With CureVac Agreement
Industry Trend Analysis - Next-Generation Sequencing Changing The Face Of Personalised Medicine
Industry Brief - Incyte Earns Milestone Payment Related To Jakavi's Reimbursement In Europe
Industry Trend Analysis - Alios Acquisition Boosts J&J's HCV Combination Drug Capabilities
Industry Trend Analysis - Merck KGaA On Track With Pharma Strategy
Industry Brief - Baxter Announces Name Of New Biopharmaceutical Company
Industry Trend Analysis - Daiichi Sankyo Fuels Oncology Pipeline With Ambit Acquisition
Industry Trend Analysis - Lilly's Trulicity Approval To Pave Way For Medium-Term GLP-1 Market Domination
Industry Brief - Gilead Submits NDA For LDV/SOF FDC In Japan
Industry Trend Analysis - FDA-Approved Contrave Enters Tough And Competitive Market
Industry Brief - BMS Reports Multiple Regulatory Milestones For Opdivo In US/EU
Industry Trend Analysis - Boehringer Ingelheim Close To Market With Second Oncology Drug
Industry Brief - CHMP Issues Positive Opinion On Darunavir/Cobicistat FDC
Industry Brief - FDA Panel Votes In Favour Of Liraglutide Approval For Obesity
Industry Trend Analysis - Xtandi Approval Represents Opportunity To Take Lead In MCRPCA Market
Industry Trend Analysis - Zydelig's EU Approval Puts It Temporarily Ahead Of Imbruvica
Industry Brief - FDA Approves Spiriva Respimat Inhalation Spray For COPD
Industry Trend Analysis - BMS Strikes At Merck's Keytruda With Patent Litigation
Industry Brief - Novo Nordisk's Xultophy Approved In Europe For Type II Diabetes
Industry Trend Analysis - Abilify Successor On Course For FDA Approval In 2015
Industry Brief - FDA Accepts Vyvanse sNDA For Filing With Priority Review
Industry Brief - Daiichi Sankyo Gains Japanese Approval For Additional Indications Of Lixiana
Industry Trend Analysis - Tests To FDA's Biosimilar Pathway Intensify Naming Debate
Industry Brief - Epirus Gains Indian Biosimilar Infliximab Approval
Industry Trend Analysis - Eisai Extends Aricept's Lifecycle With Japanese Approval For DLB
Industry Brief - Lundbeck Commences European Launch Of Brintellix In Denmark
Industry Brief - Shire Reaches Final Agreement With US Government
Industry Brief - FDA Approves Movantik For Treating Opioid-Induced Constipation
Industry Trend Analysis - Amgen Vies For Swift Blinatumomab Approval
Industry Trend Analysis - Litigation Threatens Namenda Switch Plan
Industry Trend Analysis - Psoriasis Approval Raises Otezla's Blockbuster Potential
Industry Brief - CHMP Adopts Positive Opinion On Gilead's Harvoni For cHCV
Industry Trend Analysis - Blood-Based Diagnostic Opens New Market For Iressa
Industry Brief - KHK Receives Japanese Approval For G-Lasta
Industry Trend Analysis - Merck Serono To Discontinue Tecemotide Development Programme In NSCLC
Industry Trend Analysis - Novo Nordisk To Invest In Obesity Research With New Unit
Industry Trend Analysis - Gilead Acts To Secure Its Reign Over HIV-1 Market
Industry Trend Analysis - Cancer Vaccine Gains First UK Promising Innovative Medicine Designation
Industry Brief - Merck Presents First Phase III Data In Japanese Patients For Omarigliptin
Industry Brief - AbbVie's Phase III Study Shows Humira's Effectiveness In Moderate-To-Severe HS
Industry Trend Analysis - Phase III MCRC Trial Results Improve Outlook For Lilly's Cyramza
Industry Brief - Secukinumab Meets Primary/Secondary Endpoints In Two Phase III PsA Studies
Industry Brief - ODM-201 Phase III Trial Initiated In Non-Metastatic Castration-Resistant PCA
Industry Brief - Novartis' LCZ696 Shows Superiority Over Enalapril In PARADIGM-HF
Industry Brief - Positive Results Reported From Four Phase III Trials Of Alirocumab
Industry Brief - LHB589 Performs Well In Phase III Combination Trials
Industry Brief - Aricept Phase III Trial In Chinese Patients With Severe AD Meets Primary Endpoint
Industry Brief - Janssen/Bayer Expand EXPLORER Cardiovascular Programme For Xarelto
Industry Brief - Positive Phase III Data Reported For Anamorelin In NSCLC Patients With Anorexia-Cachexia
Industry Brief - Byetta Meets Primary Endpoint In Trial Versus Bolus Insulin
Industry Brief - Phase III Study Of Andexanet Alfa/Eliquis Meets Primary/Secondary Endpoints

Table Of Contents

Key Pharma News 06 OCTOBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 World Clinical Chemistry Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East—Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 75000
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both ...

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.